The Journal ofClinical Psychiatry

Supplementary Material

Article Title:	Changes in Metabolic Parameters and Body Weight in Patients With Prediabetes Treated With Adjunctive Brexpiprazole for Major Depressive Disorder: Pooled Analysis of Short- and Long-Term Clinical Studies
Author(s):	John W. Newcomer, MD; Stine R. Meehan, PhD; Dalei Chen, PhD; Malaak Brubaker, PhD; and Catherine Weiss, PhD

DOI Number: https://doi.org/10.4088/JCP.23m14786

LIST OF SUPPLEMENTARY MATERIAL FOR THE ARTICLE

- 1. <u>Table 1</u> Fasting metabolic parameters at baseline and changes at Week 6 and Week 52 of ADT + brexpiprazole or ADT + placebo therapy, stratified by diabetes status
- 2. Figure 1 Fasting serum total cholesterol: incidence of categorical shifts from baseline to any postbaseline visit during ADT + brexpiprazole or ADT placebo therapy, stratified by diabetes status
- 3. Figure 2 Fasting serum LDL cholesterol: incidence of categorical shifts from baseline to any postbaseline visit during ADT + brexpiprazole or ADT + placebo therapy, stratified by diabetes status

DISCLAIMER

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

Supplementary Material

Supplement to: Changes in metabolic parameters and body weight in patients with prediabetes treated with adjunctive brexpiprazole in major depressive disorder: pooled analysis of short- and long-term clinical studies

Supplementary Table 1. Fasting metabolic parameters at baseline and changes at Week 6 and Week 52 of ADT + brexpiprazole or ADT + placebo therapy, stratified by diabetes status

	Short-term studies				Long-term analysis	
	Non-diabetes		Prediabetes		Non-diabetes	Prediabetes
	ADT + placebo	ADT + brexpiprazole 1-3 mg	ADT + placebo	ADT + brexpiprazole 1-3 mg	ADT + brexpiprazole 0.5–3 mg	ADT + brexpiprazole 0.5-3 mg
Glucose (mg/dL)						
Baseline	87.4 (7.8) (n=315)	87.4 (7.8) (n=412)	99.8 (9.6) (n=173)	100.6 (10.7) (n=237)	89.2 (18.9) (n=1,689)	100.7 (14.9) (n=926)
Change at Week 6 ^a /Week 52 ^b	2.5 (10.6) (n=306)	2.1 (10.5) (n=391)	-1.4 (11.5) (n=168)	-2.7 (12.1) (n=224)	3.9 (20.4) (n=408)	1.9 (22.8) (n=267)
Triglycerides (mg/dL)						
Baseline	122.8 (87.9) (n=319)	120.9 (71.4) (n=413)	143.7 (82.3) (n=173)	142.0 (75.9) (n=237)	126.9 (89.6) (n=1,690)	148.5 (88.8) (n=926)
Change at Week 6ª/Week 52 ^b	-3.6 (70.3) (n=311)	0.1 (57.9) (n=393)	4.5 (70.5) (n=169)	2.3 (59.9) (n=224)	18.3 (72.9) (n=410)	12.9 (72.4) (n=273)
HDL cholesterol (mg/dL)						
Baseline	62.1 (18.1) (n=319)	61.9 (18.7) (n=413)	57.0 (16.5) (n=172)	57.1 (15.5) (n=236)	62.6 (25.4) (n=1,690)	58.0 (19.9) (n=926)
Change at Week 6 ^a /Week 52 ^b	0.7 (9.0) (n=311)	2.2 (9.0) (n=393)	0.4 (8.1) (n=168)	0.9 (7.3) (n=223)	-4.7 (15.7) (n=410)	-4.4 (16.6) (n=272)
Total cholesterol (mg/dL)						
Baseline	205.2 (39.8) (n=319)	207.1 (43.1) (n=414)	215.5 (45.3) (n=173)	214.3 (42.6) (n=237)	206.8 (46.0) (n=1,690)	212.7 (44.8) (n=926)
Change at Week 6 ^a /Week 52 ^b	0.3 (23.9) (n=311)	3.1 (25.1) (n=394)	2.2 (29.0) (n=169)	-0.3 (28.9) (n=224)	4.7 (36.8) (n=402)	5.3 (38.0) (n=260)
LDL cholesterol (mg/dL)						
Baseline	119.1 (35.6) (n=311)	121.8 (38.3) (n=407)	130.8 (40.3) (n=168)	129.0 (38.3) (n=231)	120.1 (40.8) (n=1,687)	125.7 (40.0) (n=923)
Change at Week 6 ^a /Week 52 ^b	-0.4 (20.1) (n=302)	1.1 (21.9) (n=386)	0.1 (26.8) (n=163)	-2.2 (26.0) (n=218)	3.0 (29.6) (n=402)	5.3 (31.7) (n=267)

^aShort-term studies; ^blong-term analysis (up to 58 weeks of adjunctive brexpiprazole treatment). Data are mean (SD). Non-diabetes: fasting serum glucose <100 mg/dL and HbA1c <5.7% at baseline; prediabetes: fasting serum glucose \geq 100 mg/dL and <125 mg/dL or HbA1c \geq 5.7% and <6.5% at baseline.

Abbreviations: ADT=antidepressant treatment; HbA1c=glycated hemoglobin; HDL=high-density lipoprotein; LDL=low-density lipoprotein; SD=standard deviation.

Supplementary Figure 1. Fasting serum total cholesterol: incidence of categorical shifts from baseline to any post-baseline visit during ADT + brexpiprazole or ADT + placebo therapy, stratified by diabetes status^a

a Non-diabetes First 6 weeks First 6 months Last 6 months 70 Favorable Favorable Unfavorable Favorable Unfavorable Unfavorable 60 50 41.2 39.0 38.9 36.9 35.8 36.7 Patients (%) 33.3 40 31.8 32.7 31.7 30.6 29.4 27.0 30 22.9 20 10.6 10.3 9.3 8.2 8.5 10 2.7 0 H-→N $B{\rightarrow}N$ H-→B N→B $B{\rightarrow} H$ N→H $H \rightarrow N \quad B \rightarrow N \quad H \rightarrow B$ N→B B→H N→H H→N B→N H→B N→B $B{\rightarrow} H$ N→H □ Placebo ■ Brexpiprazole Brexpiprazole Brexpiprazole N (<200 mg/dL) n=147 n=190 n=742 n=212 n=549 B (≥200 to <240 mg/dL) n=118 n=139 n=180 H (≥240 mg/dL) n=54 n=85 n=350 n=107 **b** Prediabetes First 6 weeks First 6 months Last 6 months 70 Favorable Favorable Unfavorable Favorable Unfavorable Unfavorable 60 50 41.7 37.7 37.7 36.8 Patients (%) 35.8 36. 40 32.0 31.6 31.6 31.8 32.2 30.0 27.2 30 23.7 23. 20 11.8 10.8 11.3 9.4 10 1.0


0 $H{\rightarrow}N$ B→N H →B N→B B→H N-→H H→N B→N H→B N→B B→H N→H H→N B→N H→B N→B B→H N→H □ Placebo ■ Brexpiprazole Brexpiprazole Brexpiprazole N (<200 mg/dL) n=362 n=64 n=95 n=127 B (≥200 to <240 mg/dL) n=81 n=320 n=106 n=59 H (≥240 mg/dL) n=223 n=80 n=50 n=61

^aPercentages are relative to the number of patients in each baseline total cholesterol category with a baseline and post-baseline measurement, given below each figure. Non-diabetes: fasting serum glucose <100 mg/dL and HbA1c <5.7% at baseline; prediabetes: fasting serum glucose \geq 100 mg/dL and <125 mg/dL or HbA1c \geq 5.7% and <6.5% at baseline.

Abbreviations: ADT=antidepressant treatment; B=borderline; H=high; HbA1c=glycated hemoglobin; N=normal.

It is illegal to post this copyrighted PDF on any website. • © 2023 Copyright Physicians Postgraduate Press, Inc.

Supplementary Figure 2. Fasting serum LDL cholesterol: incidence of categorical shifts from baseline to any post-baseline visit during ADT + brexpiprazole or ADT + placebo therapy, stratified by diabetes status^a



^aPercentages are relative to the number of patients in each baseline LDL cholesterol category with a baseline and post-baseline measurement, given below each figure. Non-diabetes: fasting serum glucose <100 mg/dL and HbA1c <5.7% at baseline; prediabetes: fasting serum glucose \geq 100 mg/dL and <125 mg/dL or HbA1c \geq 5.7% and <6.5% at baseline.

Abbreviations: ADT=antidepressant treatment; B=borderline; H=high; HbA1c=glycated hemoglobin; LDL=low-density lipoprotein; N=normal.

It is illegal to post this copyrighted PDF on any website. • © 2023 Copyright Physicians Postgraduate Press, Inc.